TIL therapy is one of the first forms of adoptive cell therapy use in cancer, but doesn’t always prove effective. One reason for this problem is that the T cells most specific for targeting tumor antigens are the ones that have been rendered most dysfunctional in the tumor microenvironment. To combat against this dysfunction, our lab is targeting T cell metabolism bolstering compounds to improve T cell efficacy.